Pfizer Inc. (PFE) — ESG & Values Scores

Environment story

Provided filings (10-K, proxy) contain no quantified Scope 1/2/3 emissions data, no disclosed net-zero target year, and no verified physical decarbonization capital investments. Deductions applied per rubric for undisclosed Scope 3 trajectory and absent/undefined net-zero commitment; a moderate controversy deduction reflects generic legal-risk language referencing 'actual or alleged environmental contamination' and climate-related disruption risk, without specific case detail. This is a research-only assessment; it does not constitute investment advice.

Criticisms on file

Generic risk-factor language referencing 'actual or alleged environmental contamination' as part of legal defense cost exposure; no specific site, fine, or quantified controversy detailed in the provided filing excerpts.
Source: PFE_10k.txt - Item 1A Risk Factors, Government Regulation and Legal Proceedings

Disclosed initiatives

Climate Change Program Oversight

Governance Committee is stated to oversee a 'climate change program,' but no specifics on emissions targets, renewable procurement, or capital projects were disclosed in the provided text.

Social story

Provided documents do not disclose a numeric CEO-to-median-worker pay ratio, workforce/leadership diversity percentages, or turnover rate, so no rubric deductions were applied for these unverified items. No documented union-suppression activity or major strikes within the last 24 months appear in the source text. This is a research-only assessment; it does not constitute investment advice.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Accord for a Healthier World

Program providing Pfizer's patented and off-patent medicines/vaccines for which it holds global rights on a not-for-profit basis to 1.2 billion people in 45 lower-income countries.

Access to medicines expansion in low-income markets
TrumpRx.gov / U.S. Government Pricing Agreement

Voluntary agreement to offer discounts (up to 85%, average 50%) on select medicines to U.S. patients via a government-linked platform.

Reduced patient out-of-pocket costs for select products

Governance story

Board is disclosed as exclusively independent directors except the combined Chairman/CEO, indicating independence above the 75% threshold, so no deduction applied there. A single-class share structure is implied (no dual-class disclosure found). Minor deductions were applied for lobbying activity related to pricing/regulatory policy engagement and for broad legal-proceeding risk exposure (False Claims Act, AKS, pricing litigation) referenced generically in the filings, though no specific active antitrust or fraud judgment was quantified in the provided text. A shareholder proposal for an independent board chair was opposed by the Board and is pending vote. This is a research-only assessment; it does not constitute investment advice.

Criticisms on file

Say-on-Pay proposal received only 54.7% support in 2025 (vs. 93.5% historical average), driven by shareholder objection to 2024 long-term incentive award modifications ('in-flight LTI awards').
Source: PFE_proxy.txt - Investor Outreach / Executive Compensation Summary
Shareholder proposal (Item 5, 2026 proxy) requesting an Independent Board Chair policy; Board unanimously recommended voting AGAINST; prior 2024 vote on similar proposal received 34.9% support.
Source: PFE_proxy.txt - Shareholder Proposal Item 5

Disclosed initiatives

Governance Committee Oversight of Political & Lobbying Activity

Governance Committee is informed of political spending policies, lobbying priorities, and trade association engagement.

Structural oversight mechanism, but spend figures not disclosed
Board Refreshment & Independent Leadership

Lead Independent Director role with significant authority; annual evaluation of leadership structure; retirement policy capping tenure at ~15 years.

Supports independent oversight absent a separate independent chair

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Pfizer Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Pfizer Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)